Source comparison
Tesamorelin for Stubborn Belly Fat: Side Effects & Safety Profile Comparison
Injection Site Reactions 32% 11% Erythema, pruritus, pain. Resolve within 5–7 days Expected with subcutaneous peptides; rotate sites Arthralgias (Joint Pain) 18% 9% Dose-related, peaks week 4–8, often transient GH-mediated fluid retention in synovial spaces Pe
This comparison does not assign a generated winner or score.
- Injection Site Reactions
- 32%
- 11%
- Erythema, pruritus, pain. Resolve within 5–7 days
- Expected with subcutaneous peptides; rotate sites
- Arthralgias (Joint Pain)
- 18%
- 9%
- Dose-related, peaks week 4–8, often transient
- GH-mediated fluid retention in synovial spaces
- Peripheral Edema
- 12%
- 4%
- Mild, typically resolves within 4 weeks
- Monitor sodium intake; reduce dose if severe
- Carpal Tunnel Symptoms
- 8%
- 2%
- Numbness, tingling in hands. Reversible upon cessation
- GH effect on connective tissue; uncommon but documented
- Hyperglycemia/Insulin Resistance
- HbA1c +0.09%
- No change
- Transient during active treatment, reverses post-cessation
- Screen fasting glucose at baseline and week 12
- Serious adverse events were rare in clinical trials. No increased incidence of malignancy, cardiovascular events, or pituitary tumours versus placebo over 26-week treatment periods. Tesamorelin is contraindicated in patients with active malignancy (GH can promote cell proliferation), disruption of the hypothalamic-pituitary axis, or known hypersensitivity to GHRH. Pregnant or breastfeeding individuals should not use tesamorelin. Animal studies show potential fetal harm, and excretion in breast milk is unknown.
- The insulin resistance signal warrants monitoring but is not clinically significant in most patients. HbA1c elevations of 0.09% don't cross the threshold for diabetes diagnosis, and glucose parameters returned to baseline within 8 weeks of stopping treatment in the REDUCE trial extension phase. Patients with pre-existing type 2 diabetes should have tighter glycemic monitoring. Tesamorelin doesn't worsen diabetic control in well-managed patients, but poorly controlled baseline glucose (HbA1c >8%) increases the risk of hyperglycemic episodes during peak GH elevation.